Page 12 - Demo

DCS: FINISHING STRONG / BUILDING MOMENTUM INTO 2022
Brock Badger, DCS III-Beaumont
1.Focusing on targets that will have maximum impact at a territory level 2.Each call will have a clearly defined purpose with an END in mind. 3.Gain commitment for each END, and have fun while doing it
Gretchen Benkendorfer, Executive DCS-Corpus Christi
1.Double down on engagements with Rybelsus writers to build depth among Top 20 2.Focus on non-writers and Rybelsus dabblers to build breadth moving into 2022 3.Continue to focus on the superiority of the molecule vs. dulaglutide, CV data, and
maximizing the benefits of the 1mg dose (Ozempic)
Kara Barry, Senior EDCS-Houston East
1.Capitalize on the success of Rybelsus with top writers by driving excitement around the new copay offer of $10 for a 1, 2, or 3 month prescription to drive depth
2.Conduct strategic interface programs with a local NP organization and a group Endocrinology practice with a new Endocrinologist who was previously in a no access practice
3.Collaborate with our CDE Katina in 3 offices we identified as new opportunities for education due to a lack of diabetes experience with new staff
4.Continue to ask for all new injectable starts with Ozempic to create advocacy in the market as the injectable GLP-1 of choice among Endocrinologists, along with asking them to expand their use of oral Semaglutide in appropriate patients.
Yvonne Ermis, Senior EDCS-Houston West
1.Hyper-focus on 3 GLP-1 injectable writers who are Trulicity supporters but showing
great momentum with Ozempic
2.Weekly blitz with an Endocrinology group practice comprised of 4 HCPs showing
significant momentum with Ozempic
3.Continue customer continuity; Continuing to be a resource for our customers and
finding ways for patients to stay on NNI products during the donut hole and as new
deductibles begin in 2022
4.Identifying offices that do not take samples (4) and leveraging the Ozempic voucher.
We stress the importance of careful utilization, have the office track each voucher, and provide us feedback as a POD. We will continue this to close out 2021 and moving into 2022
John Guzman, Senior DCS-San Antonio Southeast
1.Maximizing all available resources. We have made it a priority to consistently highlight and promote the incredible resources available to both HCP’s and their patients beyond the usual product samples and in-office engagements (Interface, NNI affordability resources, branded materials/patient education, diabetes educator)
2.Planning out our schedule and securing as many appointments with high-value customers through the end of 2021 and into Q1 2022 to maintain a consistent presence when most companies and representatives become less engaged
3.Actively engage and partner with as many refill nurses, medical assistants, and clinic coordinators in an effort to identify potential candidates for Rybelsus/Ozempic who are currently on inferior therapies